Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing technology company, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The event is scheduled for June 3-5 in Chicago. Olivier Loeillot, President and CEO, will deliver a company overview presentation on June 3rd at 1:20 p.m. CT. Investors can access the live webcast through Repligen's Investor Relations website, with a replay available for a limited time after the event.
Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in two major investor conferences in May 2025. The company's Chief Financial Officer, Jason K. Garland, will represent Repligen at:
1. RBC Capital Markets' 2025 Global Healthcare Conference in New York (May 20-21), featuring an analyst-led discussion on May 20 at 3:35 p.m. ET
2. Craig-Hallum's 22nd Annual Institutional Investor Conference in Minneapolis (May 28)
Both events will include one-on-one meetings with investors. The RBC conference presentation will be available via live webcast on Repligen's Investor Relations website.
Repligen reported strong Q1 2025 financial results with revenue reaching $169 million, marking a 10% year-over-year increase and 14% organic non-COVID growth. The company saw orders grow nearly 20% across all franchises.
Key highlights include:
- Biopharma and consumables revenue increased over 20% year-over-year
- Completed acquisition of 908 Devices' bioprocessing portfolio
- Launched CTech™ SoloVPE® Plus System for UV-based analysis
- Adjusted operating income up 72% year-over-year
Financial metrics show improvement with GAAP gross profit at $91 million and adjusted earnings per share of $0.39. The company maintains its 2025 guidance with expected revenue of $695M-$720M and organic growth of 9.5%-13.5%. Cash position remains strong at $697 million as of March 31, 2025.
Repligen (NASDAQ:RGEN) has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025. The company will release its earnings press release before market opening, followed by a conference call at 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2025.
The conference call will be accessible via toll-free numbers: (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. A webcast will also be available through the company's Investor Relations website. Replay options include dial-in numbers (877) 344-7529 (US), (855) 669-9658 (Canada), and (412) 317-0088 (international) with passcode 6386085.
Repligen (NASDAQ:RGEN) has appointed Jacob Johnson as Vice President of Investor Relations. Johnson, who previously served as Managing Director and Research Analyst at Stephens Inc., will lead investor relations and report to CFO Jason K. Garland.
Johnson brings significant experience in the life sciences tools and pharma services sector, having covered Repligen as a research analyst since 2019. He previously worked as a research associate on Stephens' healthcare services team and in investment management. Johnson holds a B.A. in Economics and Mathematics from Sewanee and an M.S. Finance from Washington University's Olin Business School.
He succeeds Sondra Newman, who is retiring after leading global investor relations and corporate communications since 2012.
Repligen (RGEN) has acquired a bioprocessing analytics portfolio from 908 Devices for $70 million in cash. The acquisition includes four desktop devices for Process Analytical Technology (PAT) applications: MAVERICK and MAVEN for real-time monitoring and control, REBEL for cell culture media analysis, and ZipChip for product quality characterization.
The strategic purchase strengthens Repligen's PAT portfolio, enabling comprehensive analytics solutions across the entire bioprocess workflow. The acquisition includes the transfer of 908's bioprocessing team to Repligen. Meanwhile, 908 Devices will maintain focus on its handheld device portfolio for health and safety applications.
This transaction represents a significant step in Repligen's strategy to support customers' increasing adoption of digitization technologies in production processes, particularly enhancing their capabilities in upstream and downstream analytics.
Repligen (RGEN) has acquired the desktop bioprocessing analytics portfolio from 908 Devices (MASS) for $70 million in cash. The acquisition includes four PAT (Process Analytical Technology) devices: MAVERICK, MAVEN, REBEL, and ZipChip.
The acquired technologies enable real-time monitoring, control of bioprocess parameters, cell culture media analysis, and high-resolution sample separations for product quality characterization. This strategic move strengthens Repligen's PAT portfolio and expands its capabilities across the entire bioprocess workflow.
Following the transaction, 908 Devices will focus on growing its handheld device portfolio for health and safety applications. The deal includes the transfer of 908's bioprocessing team to Repligen.
Repligen (NASDAQ:RGEN) reported Q4 2024 revenue of $168 million and full-year revenue of $634 million. Q4 orders and revenues showed sequential increases of 11% and 8% respectively, with orders outpacing revenue by 6%. The company experienced strong momentum across its portfolio, with Q4 revenue growing 13% excluding COVID-related revenue, despite currency headwinds.
CDMO and capital equipment segments showed significant sequential growth, with revenues increasing approximately 20% and 30% respectively. The company completed the acquisition of Tantti Laboratory Inc and launched AVIPure® dsRNA resin for mRNA therapeutics.
For Q4 2024, GAAP net loss was $(34) million, with adjusted net income of $25 million. Full-year 2024 GAAP net loss was $(26) million, with adjusted net income of $89 million. The company provided 2025 guidance projecting 8-12% reported growth, or 10-14% excluding COVID-related revenue.
Repligen (NASDAQ:RGEN) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss business updates and financial results for the three- and twelve-month periods ended December 31, 2024.
The conference call will be available via toll-free numbers for domestic and international callers, and a webcast will be accessible through the company's Investor Relations website. Both the call and webcast will be archived for future access, with replay numbers provided for U.S., Canadian, and international callers using passcode 6188777.